Thiophenecarboxylate Suppressor of Cyclic Nucleotides Discovered in a Small-Molecule Screen Blocks Toxin-Induced Intestinal Fluid Secretion
We carried out a “pathway” screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled recept...
Saved in:
Published in | Molecular pharmacology Vol. 75; no. 1; pp. 134 - 142 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.01.2009
American Society for Pharmacology and Experimental Therapeutics |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | We carried out a “pathway” screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC50 of <5 μM for suppression of agonist-induced cAMP and cGMP elevation. Measurements of cAMP, cGMP, and downstream signaling in response to various activators/inhibitors suggested that the 2-(acylamino)-3-thiophenecarboxylates function as nonselective phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTR-mediated Cl- current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecarboxylates represent the first small-molecule cyclic nucleotide suppressors, whose potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and growth inhibition of cAMP-dependent tumors. |
---|---|
AbstractList | We carried out a "pathway" screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC(50) of <5 microM for suppression of agonist-induced cAMP and cGMP elevation. Measurements of cAMP, cGMP, and downstream signaling in response to various activators/inhibitors suggested that the 2-(acylamino)-3-thiophenecarboxylates function as nonselective phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTR-mediated Cl(-) current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecarboxylates represent the first small-molecule cyclic nucleotide suppressors, whose potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and growth inhibition of cAMP-dependent tumors.We carried out a "pathway" screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC(50) of <5 microM for suppression of agonist-induced cAMP and cGMP elevation. Measurements of cAMP, cGMP, and downstream signaling in response to various activators/inhibitors suggested that the 2-(acylamino)-3-thiophenecarboxylates function as nonselective phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTR-mediated Cl(-) current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecarboxylates represent the first small-molecule cyclic nucleotide suppressors, whose potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and growth inhibition of cAMP-dependent tumors. We carried out a "pathway" screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC(50) of <5 microM for suppression of agonist-induced cAMP and cGMP elevation. Measurements of cAMP, cGMP, and downstream signaling in response to various activators/inhibitors suggested that the 2-(acylamino)-3-thiophenecarboxylates function as nonselective phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTR-mediated Cl(-) current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecarboxylates represent the first small-molecule cyclic nucleotide suppressors, whose potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and growth inhibition of cAMP-dependent tumors. We carried out a “pathway” screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC 50 of <5 μM for suppression of agonist-induced cAMP and cGMP elevation. Measurements of cAMP, cGMP, and downstream signaling in response to various activators/inhibitors suggested that the 2-(acylamino)-3-thiophenecarboxylates function as nonselective phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTR-mediated Cl - current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecarboxylates represent the first small-molecule cyclic nucleotide suppressors, whose potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and growth inhibition of cAMP-dependent tumors. We carried out a âpathwayâ screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC 50 of <5 μM for suppression of agonist-induced cAMP and cGMP elevation. Measurements of cAMP, cGMP, and downstream signaling in response to various activators/inhibitors suggested that the 2-(acylamino)-3-thiophenecarboxylates function as nonselective phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTR-mediated Cl - current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecarboxylates represent the first small-molecule cyclic nucleotide suppressors, whose potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and growth inhibition of cAMP-dependent tumors. We carried out a “pathway” screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC50 of <5 μM for suppression of agonist-induced cAMP and cGMP elevation. Measurements of cAMP, cGMP, and downstream signaling in response to various activators/inhibitors suggested that the 2-(acylamino)-3-thiophenecarboxylates function as nonselective phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTR-mediated Cl- current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecarboxylates represent the first small-molecule cyclic nucleotide suppressors, whose potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and growth inhibition of cAMP-dependent tumors. |
Author | Padmawar, Prashant Tradtrantip, Lukmanee Yangthara, Buranee Verkman, A.S. Morrison, Christopher |
AuthorAffiliation | Departments of Medicine and Physiology, Cardiovascular Research Institute, University of California, San Francisco, California |
AuthorAffiliation_xml | – name: Departments of Medicine and Physiology, Cardiovascular Research Institute, University of California, San Francisco, California |
Author_xml | – sequence: 1 givenname: Lukmanee surname: Tradtrantip fullname: Tradtrantip, Lukmanee – sequence: 2 givenname: Buranee surname: Yangthara fullname: Yangthara, Buranee – sequence: 3 givenname: Prashant surname: Padmawar fullname: Padmawar, Prashant – sequence: 4 givenname: Christopher surname: Morrison fullname: Morrison, Christopher – sequence: 5 givenname: A.S. surname: Verkman fullname: Verkman, A.S. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/18824527$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kU2P0zAYhCO0iP2AK0fkC9xS_CaxnVyQoLBQaYFDi8TNcp03jcGxg52U7W_gT-NVlxUg7cmW_MyMPHOenTjvMMueAl0AFNXLwdsF0HpBGWVcPMjOgBWQUwA4yc4oLXheN-zraXYe4zdKoWI1fZSdQl0XFSvEWfZr0xs_9uhQq7D11werJiTreRwDxugD8R1ZHrQ1mnyatUU_mRYjeWui9nsM2BLjiCLrQVmbf_QW9WyTXgdER95Yr79HsvHXxuUr18468Ss3YZyMU5Zc2tm0ZI2Jnox3j7OHnbIRn9yeF9mXy3eb5Yf86vP71fL1Va4rLqa8EAwKJpoaFZYllKpBDi3nZcMVFSUUAoALpmpAvYVGdajaRpS87HgnhGrKi-zV0XectwO2Gt0UlJVjMIMKB-mVkf--ONPLnd_LgtepZpYMXtwaBP9jTr-RQ-oDrVUO_RwlT_G0BJ7AZ38n3UX86T8B1RHQwccYsJPaTOqmjBRsrAQqb2aWaeZ0r-Vx5iRb_Ce7c75P8Pwo6M2u_2kCyrFXYVDaW787SMEkSCirxNVHDlP_e4NBRm3Qpd2SRk-y9ea-iN82y80e |
CitedBy_id | crossref_primary_10_1021_jm200505e crossref_primary_10_1681_ASN_2015010057 crossref_primary_10_1038_ki_2009_438 crossref_primary_10_1681_ASN_2013040398 crossref_primary_10_1124_mol_109_061051 crossref_primary_10_1016_j_coph_2013_08_005 crossref_primary_10_1053_j_ackd_2010_01_006 crossref_primary_10_1016_j_cellsig_2020_109649 crossref_primary_10_1016_j_niox_2017_09_007 crossref_primary_10_1002_jcp_28094 crossref_primary_10_1097_MOG_0b013e3283358a45 crossref_primary_10_1093_ckj_sfy103 crossref_primary_10_1089_adt_2010_0313 crossref_primary_10_4155_fmc_13_42 |
Cites_doi | 10.1085/jgp.200409059 10.1124/mol.107.034496 10.1161/01.RES.0000256354.95791.f1 10.1172/JCI200318326 10.1016/S0140-6736(03)15328-7 10.1023/A:1014231722696 10.1016/j.cell.2007.09.037 10.1172/JCI0216112 10.1016/j.semnephrol.2008.03.003 10.1128/IAI.74.3.1505-1515.2006 10.1146/annurev.physiol.68.040504.094707 10.1007/s00441-006-0226-0 10.1007/s00706-003-0161-7 10.1124/mol.63.5.1094 10.1053/j.gastro.2003.11.005 10.1016/S0188-4409(99)00078-8 10.1681/ASN.2007070828 10.1152/ajpcell.1993.265.4.C859 10.1073/pnas.86.15.6007 10.1074/jbc.M212723200 10.1021/jo00141a028 10.4161/cc.5.6.2582 10.1161/01.RES.0000087541.15600.2B 10.2174/1568008054064805 10.1124/pr.58.3.5 10.1016/j.tips.2005.02.003 10.3109/00313029209068884 |
ContentType | Journal Article |
Copyright | 2006 American Society for Pharmacology and Experimental Therapeutics Copyright © 2009, The American Society for Pharmacology and Experimental Therapeutics |
Copyright_xml | – notice: 2006 American Society for Pharmacology and Experimental Therapeutics – notice: Copyright © 2009, The American Society for Pharmacology and Experimental Therapeutics |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1124/mol.108.050567 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1521-0111 |
EndPage | 142 |
ExternalDocumentID | PMC2685055 18824527 10_1124_mol_108_050567 75_1_134 S0026895X24146597 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: R01 HL073856 – fundername: NHLBI NIH HHS grantid: HL59198 – fundername: NIBIB NIH HHS grantid: EB00415 – fundername: NIDDK NIH HHS grantid: DK35124 – fundername: NIDDK NIH HHS grantid: P30 DK072517 – fundername: NHLBI NIH HHS grantid: HL73856 – fundername: NEI NIH HHS grantid: EY13574 – fundername: NIDDK NIH HHS grantid: DK72517 |
GroupedDBID | --- -~X .55 .GJ 0R~ 123 18M 2WC 34G 39C 4.4 53G 5RE 5VS AAJMC AALRI AAXUO ABCQX ABJNI ABSQV ACGFO ACGFS ADBBV ADCOW AENEX AERNN AFFNX AFHIN AFOSN ALMA_UNASSIGNED_HOLDINGS AYCSE BAWUL BTFSW CS3 DIK E3Z EBS EJD F5P F9R FDB GX1 H13 HH5 HZ~ IH2 INIJC K-O KQ8 L7B LSO M41 MVM N9A O9- OK1 P2P R.V R0Z RHF RHI ROL RPT TR2 UQL VXZ W8F WOQ X7M XOL YBU YHG ZGI ZXP - 0R 55 AALRV AAPBV ABFLS ABSGY ABZEH ADACO ADBIT DL FH7 HZ O0- X ZA5 AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c467t-275125798eae3313a9e61d66396a07312711675a81ecb19afead97363f6f77a93 |
ISSN | 0026-895X 1521-0111 |
IngestDate | Thu Aug 21 18:11:10 EDT 2025 Fri Jul 11 11:35:04 EDT 2025 Thu Apr 03 07:05:10 EDT 2025 Tue Jul 01 05:34:16 EDT 2025 Thu Apr 24 23:07:18 EDT 2025 Tue Jan 05 21:17:00 EST 2021 Sat Feb 22 15:41:36 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c467t-275125798eae3313a9e61d66396a07312711675a81ecb19afead97363f6f77a93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material. Address correspondence to: Dr. Alan S. Verkman, 1246 Health Sciences East Tower, Box 0521, University of California, San Francisco, San Francisco, CA 94143-0521. E-mail: alan.verkman@ucsf.edu This work was supported by grants DK72517, DK35124, HL59198, EY13574, EB00415, and HL73856 from the National Institutes of Health, and Research Development Program (R613) and Drug Discovery grants from the Cystic Fibrosis Foundation. ABBREVIATIONS: PDE, phosphodiesterase; CFTR, cystic fibrosis transmembrane conductance regulator; V2R, vasopressin-V2 receptor; dDAVP, desmopressin; CTX, cholera toxin; STa, Escherichia coli heat-stable toxin; CPT, chlorophenylthio; IBMX, 3-isobutyl-1-methylxanthine; FRT, Fisher rat thyroid; YFP, yellow fluorescent protein; MDCK, Madin-Darby canine kidney; CHO, Chinese hamster ovary; PBS, phosphate-buffered saline; DMSO, dimethyl sulfoxide; ES-MS, electrospray mass spectroscopy; MRP, multidrug resistance protein; PDE, phosphodiesterase; CNT, cyclic nucleotide. |
OpenAccessLink | http://doi.org/10.1124/mol.108.050567 |
PMID | 18824527 |
PQID | 66750316 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2685055 proquest_miscellaneous_66750316 pubmed_primary_18824527 crossref_citationtrail_10_1124_mol_108_050567 crossref_primary_10_1124_mol_108_050567 highwire_pharmacology_75_1_134 elsevier_sciencedirect_doi_10_1124_mol_108_050567 |
ProviderPackageCode | RHF RHI CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2009-01-01 |
PublicationDateYYYYMMDD | 2009-01-01 |
PublicationDate_xml | – month: 01 year: 2009 text: 2009-01-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Molecular pharmacology |
PublicationTitleAlternate | Mol Pharmacol |
PublicationYear | 2009 |
Publisher | Elsevier Inc American Society for Pharmacology and Experimental Therapeutics |
Publisher_xml | – name: Elsevier Inc – name: American Society for Pharmacology and Experimental Therapeutics |
References | Vaandrager (REF23) 2002; 230 Rybalkin, Yan, Bornfeldt, Beavo (REF17) 2003; 93 Miklos, Hetenyi, Sohar, Stajer (REF11) 2004; 135 Ma, Thiagarajah, Yang, Sonawane, Folli, Galietta, Verkman (REF8) 2002; 110 Murthy (REF14) 2006; 68 Sack, Sack, Nair, Siddique (REF18) 2004; 363 Barkla, Whitehead, Hayward (REF1) 1992; 24 Muanprasat, Sonawane, Salinas, Taddei, Galietta, Verkman (REF12) 2004; 124 Murakami, Kamiya, Yanagita, Mori (REF13) 1999; 30 Omori, Kotera (REF15) 2007; 100 Thiagarajah, Verkman (REF21) 2005; 26 Li, Krishnamurthy, Penmatsa, Marrs, Wang, Zaccolo, Jalink, Li, Nelson, Schuetz (REF7) 2007; 131 Thiagarajah, Broadbent, Hsieh, Verkman (REF20) 2004; 126 Crane, Choudhari, Naeher, Duffey (REF5) 2006; 74 Barrett (REF2) 1993; 265 Field (REF6) 2003; 111 Torres (REF22) 2008; 28 Yang, Sonawane, Zhao, Somlo, Verkman (REF26) 2008; 19 Reid, Wielinga, Zelcer, De Haas, Van Deemter, Wijnholds, Balzarini, Borst (REF16) 2003; 63 Wielinga, van der Heijden, Reid, Beijnen, Wijnholds, Borst (REF25) 2003; 278 Yangthara, Mills, Chatsudthipong, Tradtrantip, Verkman (REF27) 2007; 72 van Staveren, Detours, Dumont, Maenhaut (REF24) 2006; 5 Meyer, Guizzardi, Rodighiero, Manfredi, Saino, Sironi, Garavaglia, Bazzini, Bottà, Portincasa (REF10) 2005; 5 Bender, Beavo (REF3) 2006; 58 Mangoo-Karim, Uchic, Lechene, Grantham (REF9) 1989; 86 Sweeney, Avner (REF19) 2006; 326 Canonne, Belanger, Lemay (REF4) 1982; 47 Rybalkin (10.1124/mol.108.050567_REF17) 2003; 93 Sack (10.1124/mol.108.050567_REF18) 2004; 363 Murakami (10.1124/mol.108.050567_REF13) 1999; 30 Ma (10.1124/mol.108.050567_REF8) 2002; 110 Vaandrager (10.1124/mol.108.050567_REF23) 2002; 230 Omori (10.1124/mol.108.050567_REF15) 2007; 100 Reid (10.1124/mol.108.050567_REF16) 2003; 63 Torres (10.1124/mol.108.050567_REF22) 2008; 28 Yang (10.1124/mol.108.050567_REF26) 2008; 19 Canonne (10.1124/mol.108.050567_REF4) 1982; 47 Murthy (10.1124/mol.108.050567_REF14) 2006; 68 Li (10.1124/mol.108.050567_REF7) 2007; 131 Wielinga (10.1124/mol.108.050567_REF25) 2003; 278 Thiagarajah (10.1124/mol.108.050567_REF21) 2005; 26 Crane (10.1124/mol.108.050567_REF5) 2006; 74 Bender (10.1124/mol.108.050567_REF3) 2006; 58 van Staveren (10.1124/mol.108.050567_REF24) 2006; 5 Miklos (10.1124/mol.108.050567_REF11) 2004; 135 Mangoo-Karim (10.1124/mol.108.050567_REF9) 1989; 86 Field (10.1124/mol.108.050567_REF6) 2003; 111 Yangthara (10.1124/mol.108.050567_REF27) 2007; 72 Thiagarajah (10.1124/mol.108.050567_REF20) 2004; 126 Barkla (10.1124/mol.108.050567_REF1) 1992; 24 Sweeney (10.1124/mol.108.050567_REF19) 2006; 326 Meyer (10.1124/mol.108.050567_REF10) 2005; 5 Barrett (10.1124/mol.108.050567_REF2) 1993; 265 Muanprasat (10.1124/mol.108.050567_REF12) 2004; 124 |
References_xml | – volume: 30 start-page: 514 year: 1999 end-page: 521 ident: REF13 article-title: Gs alpha mutations in hyperfunctioning thyroid adenomas publication-title: Arch Med Res – volume: 93 start-page: 280 year: 2003 end-page: 291 ident: REF17 article-title: Cyclic GMP phosphodiesterase and regulation of smooth muscle function publication-title: Circ Res – volume: 63 start-page: 1094 year: 2003 end-page: 1103 ident: REF16 article-title: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance protein-MRP4 and MRP5 publication-title: Mol Pharmacol – volume: 111 start-page: 931 year: 2003 end-page: 943 ident: REF6 article-title: Intestinal ion transport and the pathophysiology of diarrhea publication-title: J Clin Invest – volume: 47 start-page: 3953 year: 1982 end-page: 3959 ident: REF4 article-title: Novel synthesis of five- and six-membered spiro g-lactones in rigid bicyclic systems publication-title: J Org Chem – volume: 126 start-page: 511 year: 2004 end-page: 519 ident: REF20 article-title: Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor publication-title: Gastroenterology – volume: 26 start-page: 172 year: 2005 end-page: 175 ident: REF21 article-title: New drug targets for cholera therapy publication-title: Trends Pharmacol Sci – volume: 5 start-page: 571 year: 2006 end-page: 572 ident: REF24 article-title: Negative feedbacks in normal cell growth and their suppression in tumorigenesis publication-title: Cell Cycle – volume: 135 start-page: 839 year: 2004 end-page: 847 ident: REF11 article-title: Preparation and structure of di-exo-condensed norbornane heterocycles publication-title: Monatsh Chem – volume: 28 start-page: 306 year: 2008 end-page: 317 ident: REF22 article-title: Vasopressin antagonists in polycystic kidney disease publication-title: Semin Nephrol – volume: 265 start-page: C859 year: 1993 end-page: C868 ident: REF2 article-title: Positive and negative regulation of chloride secretion in T84 cells publication-title: Am J Physiol – volume: 86 start-page: 6007 year: 1989 end-page: 6011 ident: REF9 article-title: Renal epithelial cyst formation and enlargement in vitro: dependence on cAMP publication-title: Proc Natl Acad Sci U S A – volume: 74 start-page: 1505 year: 2006 end-page: 1515 ident: REF5 article-title: Mutual enhancement of virulence by enterotoxigenic and enteropathogenic publication-title: Infect Immun – volume: 58 start-page: 488 year: 2006 end-page: 520 ident: REF3 article-title: Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use publication-title: Pharmacol Rev – volume: 110 start-page: 1651 year: 2002 end-page: 1658 ident: REF8 article-title: Thiazolidinone CFTR inhibitor identified by high throughput screening blocks cholera toxin-induced intestinal fluid secretion publication-title: J Clin Invest – volume: 131 start-page: 940 year: 2007 end-page: 951 ident: REF7 article-title: Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia publication-title: Cell – volume: 68 start-page: 345 year: 2006 end-page: 374 ident: REF14 article-title: Signaling for contraction and relaxation in smooth muscle of the gut publication-title: Annu Rev Physiol – volume: 100 start-page: 309 year: 2007 end-page: 327 ident: REF15 article-title: Overview of PDEs and their regulation publication-title: Circ Res – volume: 24 start-page: 296 year: 1992 end-page: 301 ident: REF1 article-title: Effects of cholera toxin on human colon carcinoma cell lines publication-title: Pathology – volume: 326 start-page: 671 year: 2006 end-page: 685 ident: REF19 article-title: Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD) publication-title: Cell Tissue Res – volume: 278 start-page: 17664 year: 2003 end-page: 17671 ident: REF25 article-title: Charcaterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells publication-title: J Biol Chem – volume: 230 start-page: 73 year: 2002 end-page: 83 ident: REF23 article-title: Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C publication-title: Mol Cell Biochem – volume: 72 start-page: 86 year: 2007 end-page: 94 ident: REF27 article-title: Small-molecule vasopressin-2 receptor antagonist identified by a G-protein coupled receptor “pathway” screen publication-title: Mol Pharmacol – volume: 124 start-page: 125 year: 2004 end-page: 137 ident: REF12 article-title: Discovery of glycine hydrazide pore occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy publication-title: J Gen Physiol – volume: 363 start-page: 223 year: 2004 end-page: 233 ident: REF18 article-title: Cholera publication-title: Lancet – volume: 19 start-page: 1300 year: 2008 end-page: 1310 ident: REF26 article-title: Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease publication-title: J Am Soc Nephrol – volume: 5 start-page: 143 year: 2005 end-page: 151 ident: REF10 article-title: Ion transport across the gall bladder epithelium publication-title: Curr Drug Targets Immune Endocr Metabol Disord – volume: 124 start-page: 125 year: 2004 ident: 10.1124/mol.108.050567_REF12 article-title: Discovery of glycine hydrazide pore occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy publication-title: J Gen Physiol doi: 10.1085/jgp.200409059 – volume: 72 start-page: 86 year: 2007 ident: 10.1124/mol.108.050567_REF27 article-title: Small-molecule vasopressin-2 receptor antagonist identified by a G-protein coupled receptor “pathway” screen publication-title: Mol Pharmacol doi: 10.1124/mol.107.034496 – volume: 100 start-page: 309 year: 2007 ident: 10.1124/mol.108.050567_REF15 article-title: Overview of PDEs and their regulation publication-title: Circ Res doi: 10.1161/01.RES.0000256354.95791.f1 – volume: 111 start-page: 931 year: 2003 ident: 10.1124/mol.108.050567_REF6 article-title: Intestinal ion transport and the pathophysiology of diarrhea publication-title: J Clin Invest doi: 10.1172/JCI200318326 – volume: 363 start-page: 223 year: 2004 ident: 10.1124/mol.108.050567_REF18 article-title: Cholera publication-title: Lancet doi: 10.1016/S0140-6736(03)15328-7 – volume: 230 start-page: 73 year: 2002 ident: 10.1124/mol.108.050567_REF23 article-title: Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C publication-title: Mol Cell Biochem doi: 10.1023/A:1014231722696 – volume: 131 start-page: 940 year: 2007 ident: 10.1124/mol.108.050567_REF7 article-title: Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia publication-title: Cell doi: 10.1016/j.cell.2007.09.037 – volume: 110 start-page: 1651 year: 2002 ident: 10.1124/mol.108.050567_REF8 article-title: Thiazolidinone CFTR inhibitor identified by high throughput screening blocks cholera toxin-induced intestinal fluid secretion publication-title: J Clin Invest doi: 10.1172/JCI0216112 – volume: 28 start-page: 306 year: 2008 ident: 10.1124/mol.108.050567_REF22 article-title: Vasopressin antagonists in polycystic kidney disease publication-title: Semin Nephrol doi: 10.1016/j.semnephrol.2008.03.003 – volume: 74 start-page: 1505 year: 2006 ident: 10.1124/mol.108.050567_REF5 article-title: Mutual enhancement of virulence by enterotoxigenic and enteropathogenic Escherichia coli publication-title: Infect Immun doi: 10.1128/IAI.74.3.1505-1515.2006 – volume: 68 start-page: 345 year: 2006 ident: 10.1124/mol.108.050567_REF14 article-title: Signaling for contraction and relaxation in smooth muscle of the gut publication-title: Annu Rev Physiol doi: 10.1146/annurev.physiol.68.040504.094707 – volume: 326 start-page: 671 year: 2006 ident: 10.1124/mol.108.050567_REF19 article-title: Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD) publication-title: Cell Tissue Res doi: 10.1007/s00441-006-0226-0 – volume: 135 start-page: 839 year: 2004 ident: 10.1124/mol.108.050567_REF11 article-title: Preparation and structure of di-exo-condensed norbornane heterocycles publication-title: Monatsh Chem doi: 10.1007/s00706-003-0161-7 – volume: 63 start-page: 1094 year: 2003 ident: 10.1124/mol.108.050567_REF16 article-title: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance protein-MRP4 and MRP5 publication-title: Mol Pharmacol doi: 10.1124/mol.63.5.1094 – volume: 126 start-page: 511 year: 2004 ident: 10.1124/mol.108.050567_REF20 article-title: Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor publication-title: Gastroenterology doi: 10.1053/j.gastro.2003.11.005 – volume: 30 start-page: 514 year: 1999 ident: 10.1124/mol.108.050567_REF13 article-title: Gs alpha mutations in hyperfunctioning thyroid adenomas publication-title: Arch Med Res doi: 10.1016/S0188-4409(99)00078-8 – volume: 19 start-page: 1300 year: 2008 ident: 10.1124/mol.108.050567_REF26 article-title: Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2007070828 – volume: 265 start-page: C859 year: 1993 ident: 10.1124/mol.108.050567_REF2 article-title: Positive and negative regulation of chloride secretion in T84 cells publication-title: Am J Physiol doi: 10.1152/ajpcell.1993.265.4.C859 – volume: 86 start-page: 6007 year: 1989 ident: 10.1124/mol.108.050567_REF9 article-title: Renal epithelial cyst formation and enlargement in vitro: dependence on cAMP publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.86.15.6007 – volume: 278 start-page: 17664 year: 2003 ident: 10.1124/mol.108.050567_REF25 article-title: Charcaterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells publication-title: J Biol Chem doi: 10.1074/jbc.M212723200 – volume: 47 start-page: 3953 year: 1982 ident: 10.1124/mol.108.050567_REF4 article-title: Novel synthesis of five- and six-membered spiro g-lactones in rigid bicyclic systems publication-title: J Org Chem doi: 10.1021/jo00141a028 – volume: 5 start-page: 571 year: 2006 ident: 10.1124/mol.108.050567_REF24 article-title: Negative feedbacks in normal cell growth and their suppression in tumorigenesis publication-title: Cell Cycle doi: 10.4161/cc.5.6.2582 – volume: 93 start-page: 280 year: 2003 ident: 10.1124/mol.108.050567_REF17 article-title: Cyclic GMP phosphodiesterase and regulation of smooth muscle function publication-title: Circ Res doi: 10.1161/01.RES.0000087541.15600.2B – volume: 5 start-page: 143 year: 2005 ident: 10.1124/mol.108.050567_REF10 article-title: Ion transport across the gall bladder epithelium publication-title: Curr Drug Targets Immune Endocr Metabol Disord doi: 10.2174/1568008054064805 – volume: 58 start-page: 488 year: 2006 ident: 10.1124/mol.108.050567_REF3 article-title: Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use publication-title: Pharmacol Rev doi: 10.1124/pr.58.3.5 – volume: 26 start-page: 172 year: 2005 ident: 10.1124/mol.108.050567_REF21 article-title: New drug targets for cholera therapy publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2005.02.003 – volume: 24 start-page: 296 year: 1992 ident: 10.1124/mol.108.050567_REF1 article-title: Effects of cholera toxin on human colon carcinoma cell lines publication-title: Pathology doi: 10.3109/00313029209068884 |
SSID | ssj0014580 |
Score | 2.039561 |
Snippet | We carried out a “pathway” screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the... We carried out a âpathwayâ screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the... We carried out a "pathway" screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the... We carried out a “pathway” screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the... |
SourceID | pubmedcentral proquest pubmed crossref highwire elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 134 |
SubjectTerms | Animals Cell Line Cells, Cultured CHO Cells Cholera Toxin - antagonists & inhibitors Cricetinae Cricetulus Cyclic AMP - metabolism Cyclic GMP - metabolism Cystic Fibrosis Transmembrane Conductance Regulator - metabolism Disease Models, Animal Dogs Inorganic Chemicals - chemical synthesis Inorganic Chemicals - chemistry Inorganic Chemicals - metabolism Intestinal Secretions - metabolism Kidney - cytology Mice Mice, Inbred Strains Molecular Structure Nucleotides, Cyclic - analysis Nucleotides, Cyclic - antagonists & inhibitors Polycystic Kidney Diseases - drug therapy Rats Rats, Inbred F344 Stereoisomerism Structure-Activity Relationship Thyroid Gland - cytology Thyroid Gland - metabolism Transfection |
Title | Thiophenecarboxylate Suppressor of Cyclic Nucleotides Discovered in a Small-Molecule Screen Blocks Toxin-Induced Intestinal Fluid Secretion |
URI | https://dx.doi.org/10.1124/mol.108.050567 http://molpharm.aspetjournals.org/content/75/1/134.abstract https://www.ncbi.nlm.nih.gov/pubmed/18824527 https://www.proquest.com/docview/66750316 https://pubmed.ncbi.nlm.nih.gov/PMC2685055 |
Volume | 75 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKeOEFcadchh_QeOgyyL1-RGhjQt3oQyeVJ8txHBatTaomESt_gb_Aj-WcONfRistLVDmO6_Z89rnk-DuEvLZ9BWozsIzIjhiGbhxjHPqmIcB7jtjYMUOJh5PPzr3TC-fT3J0PBj87WUtFHhzJ71vPlfyPVKEN5IqnZP9Bss2g0ACfQb5wBQnD9S9lHCMtQKKkWAfp9WYBhuMoK1Zlcmtaxv_lRiKNdYK0xWkehyrDdzISEzcV0i6NxChbisXCWOo6ufC8xFQczGiXV0j_cB0nBjjuhSz758jKgRZstCjicJSh1dnItq4MVZfcHa1aYuwmdA_aMcxBQ-ZxWRpvUlwtRaIafH0RydccWaRL5BXr7r2pCJfim04Jn65FdinarJ2zdF2WU7zBmNCLarBOVKPaiC1sqDZitaWt2r113ZUeSvVWbOog6e8qwnJArvCnYnrlERby0_VA-lzc55_5ycVkwmfH89ktctsCJwTrY3ycNwlEpuOWdfmaWVWUoDD-2_7ou0yehpF6m3dzM0m3Y_XM7pG7lbtC32vs3ScDlTwgB1Mt1s0hnbXH97JDekCnHYE_JD-2AZS2AKVpRDVAaQegtAUojRMqaB-gVAOUaoDSHkBpC1BaApQ2AH1ELk6OZx9Ojar6hyFBeeeG5YMt6vpsrISybdMWTHlmCAYy8wToJdPy8RWiK8amkoHJRAR7IvNtz468yPcFsx-TvSRN1FNCmftOWIqB5WpFjjcWTDgscGTAvMAKhFJDYtQC4rKixscKLQteusiWw-EnIpUu1wIdkjdN_5UmhdnZ06zlzSuTVpuqHOC485n9Ghi8u0y573KTA6yH5FUNFw7KAN_wwVpMi4x7HqYlmN6QPNHgaacHnrTjWjC434NV0wFp5vt3kviypJu3vDHMy332x299Tu60S_kF2cvXhXoJJnse7Jcr5xcsOfo3 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Thiophenecarboxylate+suppressor+of+cyclic+nucleotides+discovered+in+a+small-molecule+screen+blocks+toxin-induced+intestinal+fluid+secretion&rft.jtitle=Molecular+pharmacology&rft.au=Tradtrantip%2C+Lukmanee&rft.au=Yangthara%2C+Buranee&rft.au=Padmawar%2C+Prashant&rft.au=Morrison%2C+Christopher&rft.date=2009-01-01&rft.issn=1521-0111&rft.eissn=1521-0111&rft.volume=75&rft.issue=1&rft.spage=134&rft_id=info:doi/10.1124%2Fmol.108.050567&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0026-895X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0026-895X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0026-895X&client=summon |